Condensed vs. Standard Step‐Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma

Le résumé fourni par la source

OBJECTIVE: To compare the incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) between two different step-up dosing (SUD) schedules with talquetamab, the standard SUD schedule of Days 1, 4, 7, and 10 and a condensed SUD schedule of Days 1, 3, 5, and 7. METHODS: We conducted a multicenter retrospective study across seven academic medical centers in the United States and included patients who received talquetamab for the treatment of relapsed/refractory multiple myeloma. The incidence and grade of severity of CRS and ICANS were compared between patients receiving the standard SUD schedule and the condensed SUD schedule. RESULTS: A total of 144 patients were included in our analysis; 33 received the standard SUD schedule and 111 received the condensed SUD schedule. The incidence of CRS (76% vs. 56%; p = 0.101) and ICANS (9% vs. 16%; p = 0.41) was similar between the standard and condensed SUD cohorts. There was no significant difference in the severity of CRS and ICANS between both cohorts. CONCLUSION: Shortening the interval between talquetamab SUDs appears feasible and well-tolerated in routine clinical practice.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.